LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglawpc.com) announces that it has filed a class action lawsuit against Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline. The new lawsuit has been filed on behalf of options purchasers and sellers.
If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 708, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the complaint, the Company issued materially false and misleading statements to investors regarding the efficacy and safety of Eravacycline, and attendant capacity for approval by both the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”).
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.